Literature DB >> 2979222

Review: loperamide--a potent antidiarrhoeal drug with actions along the alimentary tract.

H Ruppin1.   

Abstract

The synthetic opioid, loperamide, reduces stool weight, frequency of bowel movements, urgency and faecal incontinence in acute and chronic diarrhoea. In man, the mechanism of action of loperamide is primarily the retardation of small-intestinal transit, and the stimulation of anal sphincter pressure and of faecal continence. This mechanism increases mucosal contact time, allowing more complete absorption of electrolytes and water. Studies in animals have demonstrated inhibitory effects of opiates and opioids, including loperamide, on fluid and electrolyte secretion induced by various secretagogues. By comparison, opiates have smaller if any antisecretory or pro-absorptive actions in man. The discrepancies between the results obtained in animal and human experiments are most certainly due to the large differences between drug doses used. Besides its opiate-receptor binding and stimulating activity, loperamide also behaves as a calcium-calmodulin antagonist and as a calcium channel blocker. These two other mechanisms might contribute to loperamide's antidiarrhoeal activity. Loperamide is more effective and safer than other opiates or opioid drugs in the treatment of both infantile and adult diarrhoea of various causes, although adequate fluid and electrolyte replacement remain the prime need.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2979222     DOI: 10.1111/j.1365-2036.1987.tb00617.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults.

Authors:  Hwang-Huei Wang; Ming-Jium Shieh; Kuan-Fu Liao
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

2.  Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea.

Authors:  P Baumer; E Danquechin Dorval; J Bertrand; J M Vetel; J C Schwartz; J M Lecomte
Journal:  Gut       Date:  1992-06       Impact factor: 23.059

Review 3.  [Treatment of diarrhea with loperamide in palliative medicine. A systematic review].

Authors:  T Pastrana; W Meißner
Journal:  Schmerz       Date:  2013-04       Impact factor: 1.107

Review 4.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

Review 5.  Management of patients with faecal incontinence.

Authors:  Jakob Duelund-Jakobsen; Jonas Worsoe; Lilli Lundby; Peter Christensen; Klaus Krogh
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

6.  Conservative treatment for anal incontinence.

Authors:  Dan Carter
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-03-18

7.  Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.

Authors:  Brian E Lacy; William D Chey; Brooks D Cash; Anthony J Lembo; Leonard S Dove; Paul S Covington
Journal:  Am J Gastroenterol       Date:  2017-04-18       Impact factor: 10.864

8.  Gastric Emptying and Gastrointestinal Transit Compared among Native and Hydrolyzed Whey and Casein Milk Proteins in an Aged Rat Model.

Authors:  Julie E Dalziel; Wayne Young; Catherine M McKenzie; Neill W Haggarty; Nicole C Roy
Journal:  Nutrients       Date:  2017-12-13       Impact factor: 5.717

9.  Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.

Authors:  Darren M Brenner; Gregory S Sayuk; Catherine R Gutman; Esther Jo; Steven J R Elmes; Louis W C Liu; Brooks D Cash
Journal:  Am J Gastroenterol       Date:  2019-09       Impact factor: 10.864

10.  Efficacy of opioid receptor modulators in patients with irritable bowel syndrome: A systematic review and meta-analysis.

Authors:  Xia Li; Bo Li; Jiaqi Zhang; Ting Chen; Haomeng Wu; Xiaoshuang Shi; Jinxin Ma; Jinyan Qin; Xudong Tang; Fengyun Wang
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.